DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Mangalam Drugs And Organics Limited — Retirement

NSE 2 hrs ago·24 Sept 2026, 1:03 pm

Company NSE

Mangalam Drugs And Organics Limited has announced the retirement of a senior executive from its board of directors. This move signals a change in the company's leadership structure as the individual steps down from their role.

For investors, this development is primarily a routine corporate governance update. It reflects the natural turnover in management roles and does not inherently signal any operational or financial shifts within the company. The company will likely appoint a successor to maintain continuity in its strategic direction.

Investors should monitor the company's official filings for any announcements regarding the appointment of the new director. This ensures they stay informed about the new leadership dynamics and any potential impact on the company's future plans.